2 terminated, 2 unknown, 1 completed, 1 recruiting. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 2, Unknown 2, Completed 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Lung Neoplasm: new trials by email Literature Review of Lung Neoplasm trials Research Report on Lung Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. Camrelizumab combined with Apatinib, Etoposide and Cisplatin - Lung Neoplasm, Small Cell Lung Cancer | Phase 3 | Unknown | Fuzhou General Hospital | 45 | 2020-08-01 | 2021-02-08 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Pralsetinib, Carboplatin, Cisplatin - RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm | Phase 3 | Terminated | Hoffmann-La Roche | 223 | 2020-07-24 | 2026-03-05 |
| Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE) Tinzaparin Sodium - Venous Thromboembolism, Lung Neoplasm | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 59 | 2018-09-14 | 2022-11-17 |
| RCT Comparing 19Ga vs 22Ga EBUS-TBNA Needles in Carcinoma. EBUS-TBNA needle - Lung Neoplasm | Phase 3 | Unknown | KU Leuven | 78 | 2016-05-01 | 2016-09-20 |
| Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy Lucanix™, Placebo Comparator - Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA | Phase 3 | Completed | NovaRx Corporation | 532 | 2008-07-01 | 2015-05-08 |
Lung Neoplasms (6) · Neoplasms (2) · Adenocarcinoma (1) · Bronchial Diseases (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1) · Lung Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1)
Lung Diseases (5) · Neoplasms by Site (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Neoplasms (4) · Bronchial Neoplasms (2) · Adnexal Diseases (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Carcinoma, Bronchogenic (1) · Cardiovascular Diseases (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Cisplatin (2) · 130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · Etoposide (1) · Gemcitabine (1) · Paclitaxel (1) · Pemetrexed (1) · Tinzaparin (1) · Trastuzumab (1) · apatinib (1) · belagenpumatucel L (1) · pembrolizumab (1) · pertuzumab (1) · pralsetinib (1)
Assistance Publique - Hôpitaux de Paris (1) · Cancer Research UK (1) · Fuzhou General Hospital (1) · Hoffmann-La Roche (1) · KU Leuven (1) · NovaRx Corporation (1)
United Kingdom (3) · Belgium (2) · France (2) · Netherlands (2) · Poland (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Costa Rica (1) · Germany (1) · Hungary (1) · India (1) · Ireland (1)
Guy Meyer, MD (1) · Matthew Krebs, Dr (1) · Xiong Chen (1)
2016 (1), 2019 (1), 2023 (1)